SecBot SecBot

OBIO

Orchestra BioMed Holdings, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001814114 Healthcare & Medical Devices
$5.56 +0.01 (+0.18%)
Oct 27 4:00 PM ET · prev $5.55
Market cap
$336.0M
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$11.00
+98% · range $9.00–20.00
Next earnings
Nov 16
in 20 days
1 year
+40.8%
from $3.95 · Oct 27
30 days
−5.6%
from $5.89
52-week range
$3.49–6.35
−12% from high · low Jan 30
Avg volume 20D
317.6K
Oct 20 spike 992.1K
Short interest
🔒 Subscribers only
Insider net
−$93.5K
4 buyers · 2 sellers · since Feb 12
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 1/5 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH Orchestra BioMed announced that its BACKBEAT global pivotal trial of AVIM Therapy has exceeded full…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    4 insiders bought $259.5K at an average $4.21. 2 insiders sold $353.1K. Price is 32% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 13 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED2,510,387$10.8M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,007,908$4.4M
STATE STREET CORPDOUBLED516,050$2.2M
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD349,544$1.5M
NORTHERN TRUST CORPDOUBLED343,640$1.5M
UBS Group AGDOUBLED325,773$1.4M
RENAISSANCE TECHNOLOGIES LLCADD90,000$388.4K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM65,804$283.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +98%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 23, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 15, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Sep 10, 2026BTIG
UPGRADE
UPGRADEBuy
Aug 11, 2026Piper Sandler
REITERATE
REITERATEOverweight
May 19, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
May 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$259.5K
bought · 4 insiders
$353.1K
sold · 2 insiders
+32.0%
vs their $4.21 cost
DateInsiderTypeValue
Oct 1, 2026
Sherman Darren
See Remarks
SELL$95.4K
Sep 10, 2026
Hochman David P
See Remarks
TAX W/H$19.1K
Sep 10, 2026
Hochman David P
See Remarks
TAX W/H$19.1K
Sep 3, 2026
Hochman David P
See Remarks
BUY$47.9K
Sep 1, 2026
Sherman Darren
See Remarks
SELL$74.1K
Aug 26, 2026
Aiello Joshua
Principal Accounting Officer
TAX W/H$1.1K
Aug 26, 2026
Sherman Darren
See Remarks
BUY$10.7K
Aug 26, 2026
Sherman Darren
See Remarks
TAX W/H$25.9K

Earnings setup

Estimates
Nov 16
reports in 20 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Other
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy
Oct 1, 2026 SEC
CEO Darren Sherman filed a Form 144 notice of intent to sell 15,000 shares of Orchestra BioMed common stock, valued at…
144 — Impact 3/10
Oct 1, 2026 SEC
Orchestra BioMed announced that its BACKBEAT global pivotal trial of AVIM Therapy has exceeded full enrollment, with…
8-K — Impact 6/10
Oct 1, 2026 Insider
Sherman Darren sold 15,000 shares
See Remarks @ $6.36 ($95.4K)
Sep 22, 2026 SEC
In Q2 2026, 13 institutional buyers added $13.2M in net new OBIO positions, overwhelmingly driven by mega-passive…
INST-CLUSTER — Impact 3/10
Sep 10, 2026 Insider
Hochman David P surrendered for taxes 3,283 shares
See Remarks @ $5.81 ($19.1K)
Sep 10, 2026 Insider
Hochman David P surrendered for taxes 3,283 shares
See Remarks @ $5.81 ($19.1K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,510,387 shares ($10.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
OBIO Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Oct 22, 2026
Press release
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB...
Aug 10, 2026
Earnings
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical…
Aug 10, 2026
Earnings date
OBIO Q2 2026 Earnings Scheduled — 2026-08-10
Aug 3, 2026
Earnings date
OBIO Q2 2026 Earnings Scheduled — 2026-08-03
Jul 15, 2026
Short interest
Short Interest: OBIO up 16% to 2.6M shares
Settlement 2026-07-15 | Days to cover: 10.86 | ≈4.32% of shares outstanding (est.)

SecBot reports

9 filings · 2 press releases · 1 bullish · 1 bearish · 7 neutral
All OBIO filing & press-release reports (11)